Establishment of correlation between in vitro enzyme binding potency and in vivo pharmacological activity: Application to liver glycogen phosphorylase a inhibitors

Journal of Pharmacology and Experimental Therapeutics

Volumn 317, Issue 3, 2006, Pages 1230-1237

  Yu, Li J ^a,b   Chen, Yue ^a   Treadway, Judith L ^a   McPherson, R Kirk ^a   McCoid, Scott C ^a   Gibbs, E Michael ^a   Hoover, Dennis J ^a  

^a PFIZER INC   (United States)

^b MILLENNIUM PHARMACEUTICALS INC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

3 (4 CHLOROPHENYL) N [1 (3,4 DIHYDROXYPYRROLIDIN 1 YL) 1 OXO 3 PHENYLPROPAN 2 YL]ACRYLAMIDE; 5 CHLORO N [1 (3 HYDROXYAZETIDIN 1 YL)1 OXO 3 PHENYLPROPAN 2 YL] IH INDOLE 2 CARBOXAMIDE; 5 CHLORO N [1 (4 HYDROXYPIPERIDIN 1 YL) 1 OXO 3 (4 FLUOROPHENYL)PROPAN 2 YL] IH INDOLE 2 CARBOXAMIDE; 5 CHLORO N [1 [3 (N HYDROXYIMINO)PYRROLIDIN 1 YL] 1 OXO 3 PHENYLPROPAN 2 YL] 1H INDOLE 2 CARBOXAMIDE; 5 CHLORO N [3 HYDROXY 4 (3,4 DIHYDROXYPYRROLIDIN 1 YL) 4 OXO 1 PHENYLBUTAN 2 YL] 1H INDOLE 2 CARBOXAMIDE; 5 CHLORO N [4 (TETRAHYDRO 1,1 DIOXIDO THIOPHEN 2 YL) 3 HYDROXY 4 OXO 1 PHENYLBUTAN 2 YL] 1H INDOLE 2 CARBOXAMIDE; AMIDE; ENZYME INHIBITOR; GLYCOGEN PHOSPHORYLASE; N [(N METHOXY N METHYLCARBAMOYL) 1 HYDROXY 3 PHENYLPROPAN 2 YL] 5 CHLORO 1H INDOLE 2 CARBOXAMIDE; N [1 (DIMETHYLCARBAMOYL) 1 HYDROXY 3 PHENYLPROPAN 2 YL] 5 CHLORO 1H INDOLE 2 CARBOXAMIDE; N [[N (2 HYDROXYETHYL) N ISOBUTYLCARBAMOYL]METHYL] 5 CHLORO 1H INDOLE 2 CARBOXAMIDE; N [[N (CYANOMETHYL) N CYCLOGBUTYLCARBAMOYL]METHYL] 5 CHLORO 1H INDOLE 2 CARBOXAMIDE; N [[N (CYANOMETHYL) N CYCLOPENTYLCARBAMOYL]METHYL] 5 CHLORO 1H INDOLE 2 CARBOXAMIDE; N [[N (TETRAHYDRO 2H PYRAN 4 YL) N (3 HYDROXYPROPYL)CARBAMOYL]METHYL] 5 CHLORO 1H INDOLE 2 CARBOXAMIDE; N [[N {TETRAHYDRO 2H PYRAN 4 YL) N (2 HYDROXYETHYL)CARBAMOYL]ETHYL] 5 CHLORO 1H INDOLE 2 CARBOXAMIDE; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; DIABETES MELLITUS; DRUG ACTIVITY; DRUG TISSUE LEVEL; ENZYME BINDING; EQUILIBRIUM DIALYSIS; GLYCOGEN LIVER LEVEL; HUMAN; HUMAN TISSUE; IN VIVO STUDY; LIVER HOMOGENATE; MALE; MOUSE; NONHUMAN; PRIORITY JOURNAL;

ANIMALS; BLOOD GLUCOSE; BLOOD PROTEINS; DIABETES MELLITUS, EXPERIMENTAL; ENZYME INHIBITORS; GLYCOGEN PHOSPHORYLASE, LIVER FORM; HUMANS; LIVER; MICE; MICE, INBRED STRAINS; MODELS, BIOLOGICAL; PROTEIN BINDING;

EID: 33646759962     PISSN: 00223565     EISSN: 15210103     Source Type: Journal    
DOI: 10.1124/jpet.105.100545     Document Type: Article

References (27)

1. Banker MJ, Clark TH, and Williams JA (2003) Development and validation of a 96-well equilibrium dialysis apparatus for measuring plasma protein binding. J Pharm Sci 92:967-974.
2. Barre J, Urien S, Albengres E, and Tillement JP (1988) Plasma and tissue binding as determinants of drug body distribution. Possible applications to toxicological studies. Xenobiotica 18 (Suppl 1):15-20.
3. Bickel MH, Raaflaub RM, Hellmuller M, and Stauffer EJ (1987) Characterization of drug distribution and binding competition by two-chamber and multi-chamber distribution dialysis. J Pharm Sci 76:68-74.
4. Bussolotti DL, Gammill RB, and Polivkova J (2004) inventors, Pfizer Products Inc., assignee. Preparation of substituted 1H-indole-2-carboxamides and 6H-thieno[2,3-b]pyrrole-5-carboxamides as antidiabetic agents, patent application WO2004041780.
5. Clausen J and Bickel MH (1993) Prediction of drug distribution in distribution dialysis and in vivo from binding to tissues and blood. J Pharm Sci 82:345-349.
6. Cory Kalvass J and Maurer TS (2002) Influence of nonspecific brain and plasma binding on CNS exposure: implications for rational drug discovery. Biopharm Drug Dispos 23:327-338.
7. DeGuchi Y, Terasaki T, Yamada H, and Tsuji A (1992) An application of microdialysis to drug tissue distribution study: in vivo evidence for free-ligand hypothesis and tissue binding of beta-lactam antibiotics in interstitial fluids. J Pharmacobio-Dyn 15:79-89.
8. Ercan-Fang N, Gannon MC, Rath VL, Treadway JL, Taylor MR, and Nuttall FQ (2002a) Integrated effects of multiple modulators on human liver glycogen phosphorylase a. Am J Physiol 283:E29-E37.
9. Ercan-Fang NG, Taylor MR, Gannon MC, Treadway JL, Rath VL, and Nuttall FQ (2002b) Regulation of human liver glycogen phosphorylase a by multiple modulators in the presence of an indole-site inhibitor; 2002 Jun 14-18; San Francisco, CA. American Diabetes Association 62nd Annual Meeting and Scientific Sessions 1412-P.
10. Ercan-Fang N, Taylor MR, Treadway JL, Levy CB, Genereux PE, Gibbs EM, Rath VL, Kwon Y, Gannon MC, and Nuttall FQ (2005) Endogenous effectors of human liver glycogen phosphorylase modulate effects of indole site inhibitors. Am J Physiol 289:E366-E372.
11. Fichtl B, Alexander VN, and Walter K (1991) Tissue binding versus plasma binding of drugs: general principles and pharmacokinetic consequences. Adv Drug Res 20:117-166.
12. Hoover DJ, Lefkowitz-Snow S, Burgess-Henry JL, Martin WH, Armento SJ, Stock IA, McPherson RK, Genereux PE, Gibbs EM, and Treadway JL (1998) Indole-2-carboxamide inhibitors of human liver glycogen phosphorylase. J Med Chem 41:2934-2938.
13. Hulin B, Hoover DJ, Treadway JL, and Martin WH (1996a) inventors, Pfizer Inc., assignee. Preparation of substituted indole-2-carboxamides and derivatives as glycogen phosphorylase inhibitors. U.S. patent application WO9639385.
14. Hulin B, Hoover DJ, Treadway JL, Martin WH, and Phillips D (1996b) inventors, Pfizer Inc., assignee. Preparation of substituted N-(indole-2-carbonyl)glycinamides and derivatives as glycogen phosphorylase inhibitors. U.S. patent application WO9639384.
15. Khalafallah N and Jusko WJ (1984) Determination and prediction of tissue binding of prednisolone in the rabbit. J Pharm Sci 73:362-366.
16. Martin WH, Hoover DJ, Armento SJ, Stock IA, McPherson RK, Danley DE, Stevenson RW, Barrett EJ, and Treadway JL (1998) Discovery of a human liver glycogen phosphorylase inhibitor that lowers blood glucose in vivo. Proc Natl Acad Sci USA 95:1776-1781.
17. Monanu MO and Madsen NB (1987) Distinction between substrate- and enzyme-directed effects of modifiers of rabbit liver phosphorylase a phosphatases. Biochem Cell Biol 65:293-301.
18. Pacifici GM and Viani A (1992) Methods of determining plasma and tissue binding of drugs. Pharmacokinetic consequences. Clin Pharmacokinet 23:449-468.
19. Proost JH, Wierda JM, and Meijer DK (1996) An extended pharmacokinetic/pharmacodynamic model describing quantitatively the influence of plasma protein binding, tissue binding and receptor binding on the potency and time course of action of drugs. J Pharmacokinet Biopharm 24:45-77.
20. Romer J and Bickel MH (1979) A method to estimate binding constants at variable protein concentrations. J Pharm Pharmacol 31:7-11.
21. Tracey WR, Treadway JL, Magee WP, Sutt JC, McPherson RK, Levy CB, Wilder DE, Yu LJ, Chen Y, Shanker RM, et al. (2004) Cardioprotective effects of ingliforib, a novel glycogen phosphorylase inhibitor. Am J Physiol 286:H1177-H1184.
22. Treadway JL, Mendys P, and Hoover DJ (2001) Glycogen phosphorylase inhibitors for treatment of type 2 diabetes mellitus. Exp Opin Investig Drugs 10:439-454.
23. Wagner JG (1976) Simple model to explain effects of plasma protein binding and tissue binding on calculated volumes of distribution, apparent elimination rate constants and clearances. Eur J Clin Pharmacol 10:425-432.
24. Wagner JG, Northam JI, Alway CD, and Carpenter OS (1965) Blood levels of drug at the equilibrium state after multiple dosing. Nature (Lond) 207:1301-1302.
25. Wilkinson GR (1983) Plasma and tissue binding considerations in drug disposition. Drug Metab Rev 14:427-465.
26. Wright JD, Boudinot FD, and Ujhelyi MR (1996) Measurement and analysis of unbound drug concentrations. Clin Pharmacokinet 30:445-462.
27. Wright SW, Rath VL, Genereux PE, Hageman DL, Levy CB, McClure LD, McCoid SC, McPherson RK, Schelhorn TM, Wilder DE, et al. (2005) 5-Chloroindoloyl glycine amide inhibitors of glycogen phosphorylase: synthesis, in vitro, in vivo and X-ray crystallographic characterization. Bioorg Med Chem Lett 15:459-465.